KOBE Biomedical Innovation Cluster newsletter vol.51
- September 2024 -
vol.51 September 2024
Hello!
Let us introduce one of our support activities for startups in Kobe Biomedical Innovation Cluster (KBIC).
Kansai Life Science Accelerator Program (KLSAP) is a program to support startups for their overseas business expansion. KLSAP2024 marks the fifth KLSAP, and three startups have been selected through a pitch contest to participate in a three-months online mentoring program stating from October 2024, supported by BioLabs. This program concludes with Demo Day to be held in BioLabs' base in Boston, US. We truly hope that three startups will take full advantage out of KLSAP program and get ready to start their global business development.
For more details, please access to below URL.
Three top winners of "Kansai Life Science Accelerator Program 2024" have been selected!
https://www.fbri-kobe.org/kbic/english/pressrelease/2024_09-25/
We wish all three startups the best of luck!!
If you missed our past issues of KBIC newsletter, please visit Newsletter Archive.
FBRI Editorial Team
NEWS
Cyto-Facto Inc. has concluded Memorandum of Understanding (MOU) with SanBio Co, Ltd.
We are pleased to announce that Cyto-Facto Inc. (Head Office: Chuo-ku, Tokyo; President and CEO: Shin Kawamata; referred to as "Cyto-Facto"), a CDMO engaged in the contract manufacturing of gene and cell preparations, signed a Memorandum of Understanding (MOU) with SanBio Co, Ltd. (Head Office: Chuo-ku, Tokyo; President and CEO: Keita Mori; referred to as "SanBio"). Both companies have exchanged information through quality and characteristic tests, and have confirmed the benefits of cooperation between the two companies.
Visit KBIC Website!
We help international medical business thrive in Japan with world-class research institutes and facilities.